BriaCell Therapeutics Corp. (NASDAQ:BCTXW – Get Free Report) shares were down 11.4% during trading on Thursday . The company traded as low as $0.12 and last traded at $0.15. Approximately 196,944 shares traded hands during trading, an increase of 77% from the average daily volume of 111,154 shares. The stock had previously closed at $0.17.
BriaCell Therapeutics Stock Performance
The business has a fifty day simple moving average of $0.31 and a two-hundred day simple moving average of $0.27.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
Read More
- Five stocks we like better than BriaCell Therapeutics
- Financial Services Stocks Investing
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What is Insider Trading? What You Can Learn from Insider Trading
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How to Effectively Use the MarketBeat Ratings Screener
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
